Has Susan Lynch received payments from drug or device companies?

Yes. Drug and device makers reported $2,413 in general payments to Susan Lynch across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Lynch did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Lynch come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Lynch

Family · Deland, FLNPI 1881887925

Payments from drug & device makers

$2,413in general payments, 2019–2025

Across 94 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$388
Merz North America, Inc.$359
Teva Pharmaceuticals USA, Inc.$253
Revance Therapeutics, Inc.$248
Otsuka America Pharmaceutical, Inc.$244
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
plus $721 from 12 others

What the payments were for

Food & beverage$2,35097%
Education$633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	17	$388
Merz North America, Inc.	5	$359
Teva Pharmaceuticals USA, Inc.	15	$253
Revance Therapeutics, Inc.	5	$248
Otsuka America Pharmaceutical, Inc.	10	$244
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	9	$199
Indivior Inc.	7	$162
Alkermes, Inc.	5	$105
Neurocrine Biosciences, Inc.	4	$94
Vanda Pharmaceuticals Inc.	3	$69
Sunovion Pharmaceuticals Inc.	4	$53
AbbVie	3	$53
E.r. Squibb & Sons, L.L.C.	2	$49
Lundbeck LLC	1	$32
Takeda Pharmaceuticals U.S.A., Inc.	1	$31
Axsome Therapeutics, Inc.	1	$26
Abbott	1	$25
Braeburn Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,413 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl	11	$6,089
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	34	$4,098
Buprenorphine Hcl	33	$838
Haloperidol	19	$421
Buspirone Hcl	24	$318
Quetiapine Fumarate	31	$305
Hydroxyzine Pamoate	16	$286
Risperidone	23	$252
Lamotrigine	19	$218
Duloxetine Hcl	13	$136
Venlafaxine Hcl ErVenlafaxine Hcl	13	$91
Citalopram HbrCitalopram Hydrobromide	14	$33
Topiramate	11	$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Indivior Inc.Suboxone	$162	$6,08911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Deland

John HuffakerVenice$8M
Stephanie MompointMiami$4.5M
Miguel TrujilloMiami Gardens$4.4M
Itsel Cardenas RamonMiami$1M
Lewis HarringtonTampa$954K
Adam StrosbergFort Lauderdale$859K
Danielle PharesFt Lauderdale$713K
David RodriguezHialeah$658K
Donna OrtizOrlando$417K
Patrick SzarazMiami$327K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →